Risk Factors for Mortality in Hospitalized Patients with Stenotrophomonas maltophilia Bacteremia

References

• Gulcan H, Kuzucu C, Durmaz R. Nosocomial Stenotrophomonas maltophilia cross-infection: three cases in newborns. Am J Infect Control. 2004;32(6):365–368. doi:10.1016/j.ajic.2004.07.003
   Web of Science ®Google Scholar
• Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41. doi:10.1128/CMR.00019-11
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001;32 Suppl 2:S104–13. doi:10.1086/320183
   Web of Science ®Google Scholar
• Sumida K, Chong Y, Miyake N, et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLoS One. 2015;10(7):e0133731. doi:10.1371/journal.pone.0133731
   PubMed Web of Science ®Google Scholar
• Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–608. doi:10.1007/s10096-010-0882-6
   PubMed Web of Science ®Google Scholar
• Jeon YD, Jeong WY, Kim MH, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine. 2016;95(31):e4375. doi:10.1097/MD.0000000000004375
   PubMed Web of Science ®Google Scholar
• Osawa K, Shigemura K, Kitagawa K, et al. Risk factors for death from Stenotrophomonas maltophilia bacteremia. J Infect Chemother. 2018;24:632–636. doi:10.1016/j.jiac.2018.03.011
   Web of Science ®Google Scholar
• Chung HS, Hong SG, Kim YR, et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28:62–66. doi:10.3346/jkms.2013.28.1.62
   PubMed Web of Science ®Google Scholar
• Cho SY, Kang CI, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58:581–583. doi:10.1128/AAC.01682-13
   PubMed Web of Science ®Google Scholar
• Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–108. doi:10.1016/j.jhin.2008.05.020
   PubMed Web of Science ®Google Scholar
• Ebara H, Hagiya H, Haruki Y, et al. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Intern Med. 2017;56(2):137–142. doi:10.2169/internalmedicine.56.6141
   PubMed Web of Science ®Google Scholar
• Chen Y, Suo J, Du M, et al. Clinical features, outcomes, and risk factors of bloodstream infections due to Stenotrophomonas maltophilia in a tertiary-care hospital of China: a retrospective analysis. Biomed Res Int. 2019;2019:4931501. doi:10.1155/2019/4931501
   PubMed Web of Science ®Google Scholar
• Marra AR, Bearman GM, Wenzel RP, Edmond MB. Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections. BMC Infect Dis. 2005;5(1):94. doi:10.1186/1471-2334-5-94
   Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–1803. doi:10.1111/j.1469-0691.2011.03514.x
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49(2):760–766. doi:10.1128/AAC.49.2.760-766.2005
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829. doi:10.1097/00003246-198510000-00009
   PubMed Web of Science ®Google Scholar
• Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653–1656. doi:10.1086/340707
   PubMed Web of Science ®Google Scholar
• Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53. doi:10.1053/jinf.2002.0978
   PubMed Web of Science ®Google Scholar
• Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49:3980–3981. doi:10.1128/AAC.49.9.3980-3981.2005
   PubMed Web of Science ®Google Scholar
• Alsuhaibani M, Aljarbou A, Althawadi S, et al. Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate. Antimicrob Resist Infect Control. 2021;10(1):19. doi:10.1186/s13756-021-00888-w
   Web of Science ®Google Scholar
• Duan Z, Qin J, Liu Y, et al. Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital. BMC Microbiol. 2020;20(1):294. doi:10.1186/s12866-020-01985-3
   Web of Science ®Google Scholar
• Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45(12):1602–1609. doi:10.1086/522998
   PubMed Web of Science ®Google Scholar
• Chang YT, Lin CY, Lu PL, et al. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections. J Microbiol Immunol Infect. 2014;47(1):28–35. doi:10.1016/j.jmii.2012.08.014
   Google Scholar
• Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54:2735–2737. doi:10.1128/AAC.01774-09
   PubMed Web of Science ®Google Scholar
• Kaur P, Gautam V, Tewari R. Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in North India. Microb Drug Resist. 2015;21(4):380–385. doi:10.1089/mdr.2014.0176
   Web of Science ®Google Scholar
• Hu LF, Xu XH, Li HR, et al. Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005–2014. J Chemother. 2018;30(1):25–30. doi:10.1080/1120009X.2017.1378834
   PubMed Web of Science ®Google Scholar